Business Context and Reporting Period
This Form 6-K filing by Innate Pharma S.A., a foreign private issuer, covers the month of February 2023. The report, dated February 21, 2023, serves as a vehicle to submit a press release (Exhibit 99.1) to the U.S. Securities and Exchange Commission. The registrant files annual reports under Form 20-F.
Key Financial Metrics
The filing text provided does not contain specific financial data. There are no disclosed values for revenue, profit, cash flow, margins, debt, or liquidity in this document. The filing consists solely of the cover page and an exhibit index referencing a press release.
Material Changes
No material changes versus prior periods are detailed in the provided text. The document does not include comparative financial statements or operational updates.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, guidance, outlook, risks, contingencies, or details on unusual items. These elements are likely contained within the referenced press release (Exhibit 99.1), which is not included in the input content.
Investor Verification Checklist
- Verify the content of the press release dated February 21, 2023 (Exhibit 99.1), as the financial and operational details are not present in the cover filing.
- Confirm the specific announcement made by Mondher Mahjoubi, Chairman of the Executive Board and CEO, referenced in the signature block.
- Review the company's most recent Form 20-F for the latest audited financial statements, as this 6-K does not provide them.